ReviewJournal of the advanced practitioner in oncology
Treatment Considerations for the Management of Patients With Hormone Receptor-Positive Metastatic Breast Cancer.
Review in Journal of the advanced practitioner in oncology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Article
- miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments.International journal of molecular medicine · 2019Article
- Small molecule nAS-E targeting cAMP response element binding protein (CREB) and CREB-binding protein interaction inhibits breast cancer bone metastasis.Journal of cellular and molecular medicine · 2019Article
- Metastatic Breast Cancer Presenting As Orbital Mass: A Case Report With Literature Review.Journal of global oncology · 2018Review
- Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2- metastatic breast cancer?Cancer management and research · 2018Article
- Human serum albumin-mediated apoptin delivery suppresses breast cancer cell growthOncology letters · 2017Article
- Combination Therapies in Advanced, Hormone Receptor-Positive Breast Cancer.Journal of the advanced practitioner in oncologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is among the most commonly diagnosed cancers in the United States. Despite treatment, 30% to 40% of women with early-stage or localized invasive breast cancer will eventually develop metastatic disease. Women with metastatic breast cancer (MBC) are living longer lives with the advent of new therapies. Currently, treatment for MBC can consist of a variety of approaches including chemotherapy, targeted therapy, and hormonal therapy, with disease-related, treatment-related, and patient-related factors guiding the selection and sequencing of these agents. In addition to controlling disease progression, strategies to improve or maintain quality of life are particularly important. For women with hormone receptor-positive disease, hormonal therapy is typically the first-line treatment of choice given the overall efficacy and favorable safety profiles of these agents; additional lines of other hormonal therapies are often administered upon disease progression. Other factors that must be considered by the practitioner to achieve optimal outcomes for the patient with MBC include the presence of comorbid illness and the educational, psychosocial, and supportive care needs of the patient.
Identifiers
26114012PMC4457170What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.